Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 564

1.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

2.

Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.

J Alzheimers Dis. 2012;29(2):319-27. doi: 10.3233/JAD-2011-111694.

PMID:
22233766
3.

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.

Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ.

Neurology. 2013 Mar 19;80(12):1124-32. doi: 10.1212/WNL.0b013e318288690c. Epub 2013 Feb 27.

PMID:
23446677
4.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

5.

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.

Neurobiol Aging. 2012 Oct;33(10):2272-81. doi: 10.1016/j.neurobiolaging.2011.12.017. Epub 2012 Jan 20.

PMID:
22264648
6.

Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.

Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.

J Alzheimers Dis. 2012;29(1):229-38. doi: 10.3233/JAD-2011-111349.

PMID:
22232006
7.

Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment.

Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, Aalten P, Lapuerta P, van de Pol L, van Schijndel R, de Jong R, Barkhof F, Wolz R, Rueckert D, Bocchetta M, Tsolaki M, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, Visser PJ.

Neurobiol Aging. 2013 Aug;34(8):2003-13. doi: 10.1016/j.neurobiolaging.2013.02.002. Epub 2013 Mar 27.

8.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
9.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

10.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

PMID:
29049480
11.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
12.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
13.

Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.

Eckerström C, Olsson E, Klasson N, Berge J, Nordlund A, Bjerke M, Wallin A.

J Alzheimers Dis. 2015;44(1):205-14. doi: 10.3233/JAD-141053.

PMID:
25201779
14.

CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S.

Cochrane Database Syst Rev. 2017 Mar 22;3:CD010803. doi: 10.1002/14651858.CD010803.pub2. Review.

PMID:
28328043
15.

CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.

16.

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb.

17.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

18.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

19.

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.

20.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432

Supplemental Content

Support Center